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Candida albicans is a major cause of opportunistic and life-threatening, systemic fungal
infections. Hence new antifungal agents, as well as new methods to treat fungal infections,
are still needed. The application of inhibitors of drug-efflux pumps may increase the
susceptibility of C. albicans to drugs. We developed a new fluorescence method that
allows the in vivo activity evaluation of compounds inhibiting of C. albicans transporters.
We show that the potentiometric dye 3,3′-dipropylthiacarbocyanine iodide diS-C3(3) is
pumped out by both Cdr1 and Cdr2 transporters. The fluorescence labeling with diS-C3(3)
enables a real-time observation of the activity of C. albicans Cdr1 and Cdr2 transporters.
We demonstrate that enniatin A and beauvericin show different specificities toward these
transporters. Enniatin A inhibits diS-C3(3) efflux by Cdr1 while beauvericin inhibits both
Cdr1p and Cdr2p.
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INTRODUCTION
The mechanism of resistance in yeasts to antifungal drugs is differ-
ent depending on the mode of action of the antifungals (Spamp-
inato and Leonardi, 2013). The drug-efflux system represented
by plasma membrane transporters is one of four mechanisms of
multidrug resistance in Candida albicans (Sanglard et al., 2009).
Three efflux pumps situated in the C. albicans plasma mem-
brane are responsible for decreasing the intracellular concentra-
tion of antifungals. These pumps are encoded by Candida drug
resistance (CDR1 and CDR2) and multidrug resistance (MDR1)
genes and they differ in the source of energy used for their activity
and in the specificity to the antifungals molecules (Cannon et al.,
2009).
One of the strategies used to identify the mechanism and
function of the C. albicans efflux pumps, and to screen for their
substrates and inhibitors, is the preparation of the collection
of C. albicans mutants with deletions of the CDR1, CDR2, and
MDR1 genes, which are used for investigating the molecular
mechanisms governing the regulation of multidrug transporter
genes (Coste et al., 2004, 2009). Studies of the multidrug resis-
tance process have provided important knowledge about efflux
pump gene regulation, their substrates and inhibitors, sources of
energy, and transport mechanism.
Another strategy for testing drugs’ inhibition of the efflux
pumps is to study their heterologous expression in the non-
pathogenic yeast Saccharomyces cerevisiae (Cannon et al., 2009).
Tanabe et al. (2011) cloned 28 chimeric constructs between C.
albicans Cdr1p (CaCdr1p) and Cdr2p (CaCdr2p) into S. cere-
visiae, showing that most of the transmembrane spans and the
nuclear binding domains (NBDs) are inhibitor binding sites or
affect substrate efflux. Although S. cerevisiae is a frequently chosen
yeast organism for expression and investigation of C. albicans
efflux pumps, it is important to consider the differences in the
metabolism of the two microorganisms (Rodaki et al., 2009;
Calahorra et al., 2012). Besides the obvious differences between
the two species, heterologous expression affects several other
intracellular interactions responsible for resistance to drugs. For
example, tested transporter expression level, and its interplay
with other proteins and regulations systems, could be completely
different.
Thus, it is important to develop methods that may enable real-
time observation of transporter activity fluctuations in response
to environmental factors in wild, not modified strains. To this day
the most popular method to measure activity of transporters is
using rhodamine 6G or rhodamine 123 (Clark et al., 1996) or nile
red as pump subtrates (Ivnitski-Steele et al., 2010). But methods
and knowledge about the activity of the pumps in real time is
scarce. Therefore, our purpose was to develop such a method and
to validate it by using collections of isogenic strains with deletions
of CDR1, CDR2, and MRD1 genes and by testing transporters
inhibitors.
One of the most potent inhibitors of MDR transporters are
group of enniatins, cyclic hexadepsipeptides produced by Fusar-
ium spp. Those mycotoxins have ionophoric properties but it
was shown that enniatin can interact with S. cerevisiae Pdr5p
(Hiraga et al., 2005) and C. albicans Cdr1p (Holmes et al., 2008)
and inhabit their activity. Other compound from this family,
beauvericin was observed to act synergistically with miconazole
(Fukuda et al., 2004) and ketoconazole (Zhang et al., 2007)
also suggesting its involvement in ATP binding cassette (ABC)
transporters inhibition.
Hendrych et al. (2009) developed a novel screening method
which uses potentiometric fluorescent probe diS-C3(3) that mea-
sures the kinetics and potency of inhibitors of the S. cerevisiae
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multidrug resistance pumps. In this work, we show for the first
time in C. albicans that diS-C3(3) is pumped out of the cell by
both Cdr1p and Cdr2p. We set up the method for testing new
drugs and transporters inhibitors, and we also demonstrated that
enniatin A and beauvericin are effective inhibitors of Cdr1p and
both Cdr1p and Cdr2p, respectively.
MATERIALS AND METHODS
STRAINS AND GROWTH MEDIA
The C. albicans strains used in this study (Table 1) were generous
gifts from D. Sanglard (Lausanne, Switzerland; Sanglard et al.,
1995, 1997; Sanglard and Ischer, 1996). All strains were grown
at 28°C on YPD medium with 2% glucose, 1% Bacto peptone
(Difco), and 1% yeast extract (Difco) and they were shaken at
120 rpm, as described herein. Solid medium was supplemented
with 1.5% agar.
SAMPLE PREPARATION
Cells were prepared according to Gásková et al. (1998) with mod-
ifications. Stationary cultures were prepared by growing strains
at 28°C for 24 h. A volume of 150 µl of stationary culture was
added to 20 ml of fresh YPD medium, incubated for 10 h at
28°C, and was shaken at 120 rpm. The cells were harvested by
centrifuging at 110 × g for 3 min, washed twice with deionized
water, resuspended in citrate-phosphate (CP) buffer (pH 6.0) at
OD600 = 0.1 or OD600 = 0.4 (±10%), and kept on ice.
DiS-C3(3) UPTAKE INTO CELLS
Aliquots of cell suspensions in CP buffer (3 ml, OD600 = 0.1;
1.02 × 106 cfu) were labeled with diS-C3(3) (Sigma) at a final
concentration of 5 × 10−8 M at room temperature. Fluorescence
spectra were measured every 4 min for 120 min, with gentle
stirring before each measurement, with a Fluorescence Spec-
trophotometer (HITACHI F-4500) equipped with a xenon lamp.
The excitation wavelength was 531 nm and the fluorescence range
was 560–590 nm. Scattered light was eliminated by an amber glass
filter with a cutoff wavelength of 540 nm. Where indicated herein,
2% glucose was added after 60 min and enniatin A (2 µg/ml)
(Sigma) and beauvericin (2 and 0.1 µg/ml) (Cayman) was
added after 80 min. All experiments were repeated at least three
Table 1 | Collection of C. albicans strains used in this study.
Strain Genotype Reference
CAF 2-1 ura3∆::imm434/URA3 Fonzi and Irwin (1993)
DSY 448 cdr1∆::hisG-URA3-
hisG/cdr1∆::hisG
Sanglard and Ischer (1996)
DSY 465 mdr1∆::hisG-URA3-
hisG/mdr1∆::hisG
Sanglard and Ischer (1996)
DSY 653 cdr2∆::hisG-URA3-
hisG/cdr2∆::hisG
Sanglard et al. (1997)
DSY 654 cdr1∆::hisG/cdr1∆::hisG
cdr2∆::hisG-URA3-
hisG/cdr2∆::hisG
Sanglard et al. (1997)
DSY 1050 cdr1∆::hisG/cdr1∆::hisG
cdr2∆::hisG/cdr2∆::hisG
mdr1∆::hisG-URA3-
hisG/mdr1∆::hisG
Mukherjee and Chandra
(2003)
times and means with standard deviation were used as staining
curve.
DISK DIFFUSION ASSAY
Candida cells were suspended in deionized water (McFarland
standard No. 0.5) and were streaked on YPG agar plates. Tested
antifungal agents at concentrations described herein were applied
to sterile OXOID Antimicrobial Susceptibility Test Disks, which
were then placed on the agar. Culture growth was assessed after a
48 h incubation at 28°C. In disk diffusion assays concentrations
below the one that gave inhibitory effect for a given compound
was used 1/2 MIC (minimal inhibitory concentration)for flucona-
zole determined independently for each strain.
CONFOCAL MICROSCOPY
Cell suspensions in CP buffer (5 ml, OD600 = 0.4) were stained
with 2 × 10−7 M diS-C3(3) probe for 30 and 150 min, with
2% glucose added after 60 min and enniatin A (2 µg/ml) and
beauvericin (2–40 µg/ml) added after 80 min. Aliquots of cell
suspensions were pelleted by centrifuging, washed in deionized
water, and 4 µl of samples were viewed with Leica TCS SP8 X
confocal microscope.
RESULTS
FLUORESCENT PROBE diS-C3(3) IS A SUBSTRATE FOR C. albicans Cdr1
AND Cdr2 TRANSPORTERS
Previous studies of S. cerevisiae have shown that the fluorescent
probe diS-C3(3) is a substrate for the pleiotropic drug resistance
(PDR) pumps, namely the Pdr5p and Snq2p pumps (Hendrych
et al., 2009). The observed fluorescence results from both passive
membrane-potential-dependent probe uptake and active probe
extrusion by ABC pumps. The final maximum fluorescence wave-
length (λmax) corresponds to the concentration equilibrium of
the probe. Since the λmax of free probe in solution is about
10 nm lower than that of probe bound inside the cell, higher
concentration of the probe within the cell results in higher λmax
(red shift). The magnitude of this red shift decreases when the
probe accumulation in the cell is lowered by the action of probe-
expelling pumps; the extent of this lowering thus reflects relative
activity of the transporters. To determine whether diS-C3(3) is
suitable for measuring transporter activity in C. albicans and
to determine which pumps are responsible for its export, we
monitored fluorescence in a collection of strains which expressed
all pumps (wild type, WT), or which lacked the Cdr1, Cdr2,
or Mdr1 pump (Table 1; Figures 1A,B). A maximum red shift
was measured in a strain with simultaneous deletion of both
Cdr1p and Cdr2p and a strain lacking all three transporters–
Cdr1, Cdr2, and Mdr1. Mutants lacking Cdr1p or Cdr2p stained
more intensely than the parent strain (Figure 1A). This means
that diS-C3(3) is actively expelled from C. albicans cells and
serves as the substrate for the two Cdr transporters but not
for Mdr1.
In the strain lacking Cdr2p the final λmax was higher, and thus
the intracellular concentration of the probe was higher than in
strain lacking Cdr1p. This indicates that under these conditions
Cdr2p plays a larger role in lowering of the probe concentration
in stained cells than Cdr1p.
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FIGURE 1 | Fluorescence of diS-C3(3) probe in strains with deleted
transporters and wild-type strain. Probe was added at the beginning of
the experiment and 2% glucose was added at the 60 min point.
Fluorescence in the strains was measured every 4 min. The probe is
exported by the ABC transporters Cdr2 and, after addition of glucose,
Cdr1—but not by the MFS family transporter Mdr1 (N = 3–4).
ENNIATIN A AND BEAUVERICIN INHIBIT TRANSPORTERS WITH
DIFFERENT SPECIFICITY
Fluorescent probes enabling the measurement of transporter
activity in real time are valuable tools for screening new pump
inhibitors. We tested the influence of a known inhibitor of Cdr1,
enniatin A, on the transporter activity measured by fluorescence
(Figures 2A,B). Addition of enniatin A to yeast cells resulted in
a red shift of the fluorescence maximum of the probe in strains
expressing Cdr1p, showing that the inhibitor is specific for Cdr1p
and does not affect the activity of Cdr2p (Figure 2B).
After validation of the method with enniatin A, we tested the
specificity of a new C. albicans CDR pump inhibitor, beauvericin
(Figure 3). This inhibitor has been found to increase cell sensitiv-
ity to miconazole (Fukuda et al., 2004). But, to our knowledge, its
specificity toward C. albicans transporters has never been tested.
In contrast to enniatin A, which affects the activity of only
Cdr1p (Figure 2), beauvericin inhibited the activity of both Cdr1p
and Cdr2p (Figure 3). As shown by diS-C3(3) efflux, Cdr1p was
more sensitive to beauvericin than Cdr2p.
To observe the activity of enniatin A and beauvericin as
inhibitors of ABC transporters in real time, we monitored the
accumulation of diS-C3(3) in C. albicans strains which express
all pumps or lack Cdr1 and Cdr2 pumps using the confocal
microscopy (Figure 4). We observed similar results to those
obtained with the fluorimeter. The strain without Cdr1p pumped
diS-C3(3) out the cell faster than the strain without Cdr2p. In
strain without Cdr2p the fluorescence is visible after 30 min while
in strain without Cdr1 diS-C3(3) is mainly present outside the
cell (Figure 4). This confirms that Cdr2p plays a larger role in
lowering of the probe concentration from the cells than Cdr1p.
After application of beauvericin the probe accumulated in both
the CDR1∆ and CDR2∆ strains, unlike enniatin A in which
activity as an inhibitor of probe efflux was observed only in the
CDR2∆ strain (Figure 4). This result confirms our observation
that beauvericin inhibited the activity of both Cdr1p and Cdr2p.
Inhibition of C. albicans transporters observed by using the
fluorescent probe diS-C3(3) should enable the screening for new
drugs. We performed disk diffusion chemosensitization assays:
paper disks containing fluconazole, alone, inhibitors (enniatin A,
beauvericin), or combination of both were placed on plates seeded
with C. albicans (Figure 5). The concentration of fluconazole
was matched to the strain sensitivity so that it did not generate
a growth inhibition zone. In case of strains expressing Cdr1p
(C. albicans WT, C. albicans MDR1∆ or C. albicans CDR2∆) inhi-
bition zones were observed after addition of enniatin A or beau-
vericin together with fluconazole. This effect was not observed
when the strains without Cdr1p were used. The combination
of enniatin A with fluconazole increased the sensitivity of the
strains in the same way shown by the fluorescence measurements
(Figure 2). Beauvericin did inhibit probe export by both Cdr1 and
Cdr2 (Figure 2), but it increased the sensitivity of the strain with-
out Cdr2, not the strain without Cdr1 to fluconazole (Figure 5).
This show further differences in the specificity of the inhibitors
against diS-C3(3) and fluconazole.
DISCUSSION
Multidrug resistance is a feature that causes serious medical
problems associated with an increasing prevalence and diversity
of fungal infections. This process was at first studied in the
non-pathogenic yeast S. cerevisiae (Kolaczkowska and Goffeau,
1999; Rogers et al., 2001). But recently, investigators are focusing
on pathogenic fungi such as C. albicans, Candida glabrata, or
Candida parapsilosis (Morschhäuser, 2010).
The fluorescent probe diS-C3(3) has been found to be a useful
tool to estimate and to continuously follow changes of the plasma
membrane potential (PMP) of whole S. cerevisiae cells (Gášková
et al., 1999), as well as to measure the kinetics of PDR pumps
(Hendrych et al., 2009).
Our results indicate that diS-C3(3) may be useful in measuring
the activity of PDR transporters in C. albicans as well. The diS-
C3(3) probe is a substrate of Cdr1p and Cdr2p, but not Mdr1p.
Previous investigations suggest that high aromatic, molecular
branching compounds are substrates for Cdr1p, probably because
of interactions with a large number of aromatic residues at an
active site of the transporter (Puri et al., 2010). The possibility
of observing the activity of efflux pumps in real time could
provide a new tool for obtaining the answers to as yet unresolved-
questions like the speed of changes in pump activity in response
to environmental factors (e.g., substrates or inhibitors).
www.frontiersin.org March 2015 | Volume 6 | Article 176 | 3
Szczepaniak et al. Inhibitors of Candida Cdr transporters
FIGURE 2 | Inhibition of ABC transporter Cdr1p by enniatin A.
DiS-C3(3) was added at the beginning of the experiment and
fluorescence was measured every 4 min in strains with or without
transporters; filled symbols indicate enniatin A addition (2 µg/ml)
at 80 min, 2% glucose was added to the sample at 60 min
(N = 3–4).
FIGURE 3 | Inhibition of ABC transporters Cdr1p and Cdr2p by
beauvericin. DiS-C3(3) was added at the beginning of the experiment
and fluorescence was measured every 4 min. Two percent glucose was
added to the sample at 60 min and beauvericin at 80 min. (A) Influence
of 1 µg/ml beauvericin on diS-C3(3) staining in C. albicans WT and
CDR1∆CDR2∆ strains. (B) Dose-dependent inhibition of diS-C3(3)
staining by beauvericin on C. albicans CDR1∆ strain. Lower lambda max
indicates more probe transported out of the cells. (C) Dose-dependent
inhibition of diS-C3(3) staining by beauvericin on C. albicans CDR2∆
strain.
DiS-C3(3) easily passes through the plasma membrane and
accumulates in the cells in response to membrane potential
(Gášková et al., 1999). The staining of C. albicans strains by
diS-C3(3) is approximately twice as slow as that of S. cerevisiae
(Figures 1A,B; Hendrych et al., 2009). The reason for this differ-
ence in the rate of staining could be a lower PMP in C. albicans
cells relative to S. cerevisiae cells. In the S. cerevisiae US 50–18C
strain, with an overexpression of major pumps Pdr5p, Snq2p, and
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FIGURE 4 | Inhibition of diS-C3(3) export by enniatin A and beauvericin.
Staining was observed by confocal microscopy at 30 min (probe loaded into
cells) and 150 min (full effect of the inhibitors).
FIGURE 5 | Disk diffusion chemosensitization assays. Paper disks
containing inhibitors (2 µg of enniatin A; 10 µg beauvericin; 1.25 µg
fluconazole for WT, MDR1∆, and CDR2∆; 0.15625 µg fluconazole for the
three remaining strains) were placed on the surface of agarose plates
seeded with yeast and the plates were incubated at 28 °C for 48 h.
Yor1p, the cell ATP level varies depending on the growth phase
and activity of PDR pumps (Krasowska et al., 2010). This is not
the case in C. albicans.
The efflux of diS-C3(3) from Candida cells was inhibited by
the depsipeptides, enniatin A, and beauvericin (Figures 2 and 3).
Hiraga et al. (2005) suggested that enniatin A is a potent and
specific inhibitor for Pdr5p, and Holmes et al. (2008) com-
plemented these data by showing that enniatin A functions as
an inhibitor of Cdr1p. Beauvericin was been found to function
as an inhibitor of miconazole efflux from C. albicans (Fukuda
et al., 2004). Enniatin A and beauvericin are ionophores that
enhance the permeability of the cell membranes for ions (Ton-
shin et al., 2010). As shown here by the inhibition of diS-
C3(3) efflux, both enniatin A and beauvericin interact with
ABC transporters (Figure 3). But beauvericin, in contrast to
enniatin A, shows a different synergism in case of flucona-
zole susceptibility (Figure 5). Similar differences in inhibitor
activity were observed for curcumin (Sharma et al., 2009), the
modulatory effect of which was restricted to rhodamine 6G or
miconazole while it had no effect on the efflux of flucona-
zole. Indeed, most of inhibitors like enniatin A (Holmes et al.,
2008), FK506 (Niimi et al., 2004), or curcumin (Sharma and
Prasad, 2011) inhibit only Cdr1p. It seems that only tetran-
drine blocks all Cdr1, Cdr2, and Mdr1 pumps (Zhang et al.,
2009). To our knowledge, our report is the first to show that
beauvericin is an inhibitor of not only Cdr1p but also of
Cdr2p. The response of transporter activity was fast (visible
after 12 min when examining gene transcription, as well as in
cell staining) yet about 40 min were necessary to reach full
activity.
CONCLUSION
In this paper we show that the carbocyanine dye diS-C3(3) is
employed in monitoring of real time activity of C. albicans ABC
transporters Cdr1 and Cdr2. This method can be used as a pow-
erful tools in the fight against multidrug resistance. Furthermore
we present that two depsipeptides: enniatin A and beauvericin act
as inhibitors of Cdr1p or Cdr1p and Cdr2p, respectively.
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